Physician Views: Benchmarking new and late-stage psoriasis drugs

The continued emergence of novel biologics which are well positioned to compete with the entrenched TNF inhibitor class makes psoriasis one of the pharma’s most dynamic and competitive markets. Our latest physician snap-poll looks to gauge the opinion of US and European dermatologists towards recent new drug launches in this disease area and rate awareness of three forthcoming launches…

Which of these newer marketed biologic agents do you expect to emerge as the most dominant treatment for plaque psoriasis?

Cosentyx (secukinumab)

Skyrizi (risankizumab)

Taltz (ixekizumab)

Tremfya (guselkumab)

Of the following recent new drug launches for plaque psoriasis, which have you been most impressed by?

Cosentyx (secukinumab)

Skyrizi (risankizumab)

Taltz (ixekizumab)

Tremfya (guselkumab)

How would you describe your expectations for the investigational-stage IL-17A and IL-17F inhibitor bimekizumab, which is currently being evaluated in Phase III studies for plaque psoriasis?

None – I don’t know enough about this agent

Very low

Low

Moderate

High

Very high

How would you describe your expectations for the investigational-stage IL-23inhibitor mirikizumab, which is currently being evaluated in Phase III studies for plaque psoriasis?

None – I don’t know enough about this agent

Very low

Low

Moderate

High

Very high

How would you describe your expectations for the investigational-stage, oral TYK-2 inhibitor BMS-986165 which is currently being evaluated in Phase III studies for plaque psoriasis?

None – I don’t know enough about this agent

Very low

Low

Moderate

High

Very high

 

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here

To read more Physician Views articles, click here.